Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (91-100 of 215) with videos related to

Pageof 22
Sort By:
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Gynecologic Oncology|February 16, 2012
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapyNoah Rodriguez, J Alejandro Rauh-Hain, Melina Shoni, et al.
Plos Biology|August 30, 2018
BRAF and AXL oncogenes drive RIPK3 expression loss in cancerAyaz Najafov, Ioannis K Zervantonakis, Adnan K Mookhtiar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2020
Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 casesDavid B Chapel, Elizabeth K Lee, Annacarolina F L Da Silva, et al.
Plos One|November 23, 2013
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutationsNicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, et al.
Gynecologic Oncology|July 10, 2012
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinomaUrsula A Matulonis, Sudarshan Sharma, Sharad Ghamande, et al.
JMIR Cancer|March 10, 2025
Usability, Acceptability, and Barriers to Implementation of a Collaborative Agenda-Setting Intervention (CASI) to Promote Person-Centered Ovarian Cancer Care: Development StudyRachel A Pozzar, James A Tulsky, Donna L Berry, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerJoyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancerElizabeth Pham, Michael J Birrer, Scott Eliasof, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Pageof 22

Showing results (91-100 of 215) with videos related to

Sort By:
Pageof 22
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Gynecologic Oncology|February 16, 2012
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapyNoah Rodriguez, J Alejandro Rauh-Hain, Melina Shoni, et al.
Plos Biology|August 30, 2018
BRAF and AXL oncogenes drive RIPK3 expression loss in cancerAyaz Najafov, Ioannis K Zervantonakis, Adnan K Mookhtiar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2020
Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 casesDavid B Chapel, Elizabeth K Lee, Annacarolina F L Da Silva, et al.
Plos One|November 23, 2013
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutationsNicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, et al.
Gynecologic Oncology|July 10, 2012
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinomaUrsula A Matulonis, Sudarshan Sharma, Sharad Ghamande, et al.
JMIR Cancer|March 10, 2025
Usability, Acceptability, and Barriers to Implementation of a Collaborative Agenda-Setting Intervention (CASI) to Promote Person-Centered Ovarian Cancer Care: Development StudyRachel A Pozzar, James A Tulsky, Donna L Berry, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerJoyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancerElizabeth Pham, Michael J Birrer, Scott Eliasof, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Pageof 22